NCT01485159View on ClinicalTrials.gov

Airflow Limitation in Cardiac Diseases in Europe

CompletedOBSERVATIONAL
Enrollment

3,000

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
PROCEDURE

Spirometry

assessment of lung function by spirometry

Trial Locations (15)

4

GSK Investigational Site, Dublin

9

GSK Investigational Site, Dublin

9000

GSK Investigational Site, Ghent

13347

GSK Investigational Site, Berlin

21049

GSK Investigational Site, Tradate (VA)

28046

GSK Investigational Site, Madrid

31059

GSK Investigational Site, Toulouse

41124

GSK Investigational Site, Modena

63263

GSK Investigational Site, Neu-Isenburg

570 10

GSK Investigational Site, Thessaloniki

3818 ES

GSK Investigational Site, Amersfoort

8601 ZK

GSK Investigational Site, Sneek

07010

GSK Investigational Site, Palma de Mallorca

SE-222 21

GSK Investigational Site, Lund

SE-205 02

GSK Investigational Site, Malmo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01485159 - Airflow Limitation in Cardiac Diseases in Europe | Biotech Hunter | Biotech Hunter